Intermittent preventive treatment in pregnancy with sulfadoxine–pyrimethamine and parasite resistance: cross-sectional surveys from antenatal care visit and delivery in rural Ghana

Atikatou Mama1,2,3*, Charity Ahiabor2,5, Bernard Tornyigah4, Naa Adjeley Frempong2, Kwadwo A. Kusi4, Bright Adu4, David Courtin1,4, Sandrine Houzé1,6, Philippe Deloron1, Michael F. Ofori4, Abraham K. Anang2, Frédéric Ariey3 and Nicaise Tuikue Ndam1,2*

Abstract

Background: Despite decades of prevention efforts, the burden of malaria in pregnancy (MiP) remains a great public health concern. Sulfadoxine-pyrimethamine (SP), used as intermittent preventive treatment in pregnancy (IPTp-SP) is an important component of the malaria prevention strategy implemented in Africa. However, IPTp-SP is under constant threat from parasite resistance, thus requires regular evaluation to inform decision-making bodies.

Methods: In two malaria endemic communities in the Volta region (Adidome and Battor), a cross-sectional hospital-based study was conducted in pregnant women recruited at their first antenatal care (ANC) visit and at delivery. Basic clinical and demographic information were documented and their antenatal records were reviewed to confirm IPTp-SP adherence. Peripheral and placental blood were assayed for the presence of Plasmodium falciparum parasites by quantitative polymerase chain reaction (qPCR). One hundred and twenty (120) positive samples were genotyped for mutations associated with SP resistance.

Results: At first ANC visit, P. falciparum prevalence was 28.8% in Adidome and 18.2% in Battor. At delivery, this decreased to 14.2% and 8.2%, respectively. At delivery, 66.2% of the women had taken at least the recommended 3 or more doses of IPTp-SP and there was no difference between the two communities. Taking at least 3 IPTp-SP doses was associated with an average birth weight increase of more than 360 g at both study sites compared to women who did not take treatment (p = 0.003). The Pfdrdfr/Pfdrhps quintuple mutant IRN-I-A/FGKAA was the most prevalent (46.7%) haplotype found and the nonsynonymous Pfdrhps mutation at codon A581G was higher at delivery among post-SP treatment isolates (40.6%) compared to those of first ANC (10.2%). There was also an increase in the A581G mutation in isolates from women who took 3 or more IPTp-SP.

Conclusions: This study confirms a positive impact following the implementation of the new IPTp-SP policy in Ghana in increasing the birth weight of newborns. However, the selection pressure exerted by the recommended
3 or more doses of IPTp-SP results in the emergence of parasites carrying the non-synonymous mutation on codon A581G. This constant selective pressure calls into question the time remaining for the clinical utility of IPTp-SP treatment during pregnancy in Africa.

**Keywords:** Malaria, Pregnancy, *Plasmodium falciparum*, Ghana, IPTp-SP, SP resistance

### Background

In sub-Saharan Africa where malaria is still endemic, pregnant women commonly suffer from malaria in pregnancy (MiP) resulting in low birth weight (LBW), maternal anaemia, and increased risk of infant mortality during the first years of life. The pathophysiology of MiP is associated with the ability of *Plasmodium falciparum*, the species accounting for more than 90% of the world’s malaria mortality, to sequester in the intervillosous spaces of the placenta through interaction with the parasite ligand VAR2CSA [1–5]. To reduce the burden of MiP on pregnant women in sub-Saharan Africa, the World Health Organization (WHO) has recommended a set of measures including the preventive treatment with sulfadoxine-pyrimethamine (SP) of all pregnant women in the second trimester of pregnancy [6–9]. Although the adaptation and use of intermittent preventive treatment of malaria in pregnancy (IPTp) has been shown to be effective in averting LBW across different SP-resistant settings [10, 11], this treatment has often fallen short of the WHO’s expectations. Several studies showed that the two-dose regimen initially recommended was inadequate in protecting neonates from the deleterious effects of MiP during the third trimester [12–14]. This together with a beneficial dose-dependent effect of IPTp-SP on birth weight and the SP alternatives with similar advantages on birth weight caused the WHO to revise its policy and recommended a monthly uptake of IPTp-SP from the second trimester of pregnancy [12]. However, concern is growing as regards the effect of increased SP uptake on the emergence of drug-resistant malaria parasites. This has a particular resonance in sub-Saharan Africa, where there is already a noticeable increase and spread of resistance to SP [15] and to date, no other alternative drug with the same benefits as SP has been identified [16].

Indeed, a recent study mediation analysis of three trials comparing the overall malaria and non-malaria effects of IPTp-SP versus IPTp with dihydroartesunate-piperazine (DP) showed that IPTp-DP was superior to IPTp-SP when considering malaria-specific endpoints, but IPTp-SP had better efficacy in improving birth weight [17]. Another study made in a low transmission area (The Gambia) also demonstrated that risk of LBW declined as the number of IPTp-doses increased and appeared lowest among women who received three doses [18].

Like most sub-Saharan countries, Ghana adopted and intensified the implementation of the revised WHO policy in 2013 [3, 19], with pregnant women taking a higher number of IPTp-SP doses starting from the second trimester of pregnancy. Thus, requiring regular evaluation to preserve the intended benefit of the policy change. In Ghana, a study carried out two years after the revised policy implementation by Quakyi and colleagues in urban and peri-urban areas showed a correlation between increased birth weight and increased uptake of IPTp-SP doses [5]. Another study in rural Northern Ghana demonstrated an association between increased IPTp-SP dosage (≥ 3) and a better birth outcome [8]. However, the majority of these investigations were carried out in urban communities where malaria infection is low and resources are abundant. In the present study, pregnant women were recruited in two malaria endemic rural and semi-urban areas in the Volta region of Ghana in order to assess IPTp-SP coverage, SP resistance, and its consequences on health of both mothers and their newborn infants.

### Methods

#### Study sites

The study was conducted between November 2016 and March 2019 in two distinct malaria endemic communities of the Volta region of Ghana: Battor and Adidome. Battor is a semi-urban community and the administrative capital of the North Tongu District and situated 6° 4′ 0″ North, 0° 25′ 0″ East. The primary health care service in the district is mainly provided by the Battor Catholic Hospital with the support of local Community-based Health Planning and Services (CHIPS) compounds. Adidome is a rural community located 50 km East of Battor and is the administrative capital for the Central Tongu District. Primary health care is provided by the district hospital located in Adidome and also supported by a number of CHIPS compounds. Malaria transmission in these areas is perennial with two transmission peaks during rainy seasons in April-July and September–November. The entomological inoculation rate (EIR) for the Volta region was approximately 65 (95% CI: 0–143) infectious bites per person per year in 2008 [9] and the main vector is *Anopheles gambiae*.

Like most sub-Saharan countries, Ghana adopted and intensified the implementation of the revised WHO policy in 2013 [3, 19], with pregnant women taking a higher number of IPTp-SP doses starting from the second trimester of pregnancy. Thus, requiring regular evaluation to preserve the intended benefit of the policy change. In Ghana, a study carried out two years after the revised policy implementation by Quakyi and colleagues in urban and peri-urban areas showed a correlation between increased birth weight and increased uptake of IPTp-SP doses [5]. Another study in rural Northern Ghana demonstrated an association between increased IPTp-SP dosage (≥ 3) and a better birth outcome [8]. However, the majority of these investigations were carried out in urban communities where malaria infection is low and resources are abundant. In the present study, pregnant women were recruited in two malaria endemic rural and semi-urban areas in the Volta region of Ghana in order to assess IPTp-SP coverage, SP resistance, and its consequences on health of both mothers and their newborn infants.

### Methods

#### Study sites

The study was conducted between November 2016 and March 2019 in two distinct malaria endemic communities of the Volta region of Ghana: Battor and Adidome. Battor is a semi-urban community and the administrative capital of the North Tongu District and situated 6° 4′ 0″ North, 0° 25′ 0″ East. The primary health care service in the district is mainly provided by the Battor Catholic Hospital with the support of local Community-based Health Planning and Services (CHIPS) compounds. Adidome is a rural community located 50 km East of Battor and is the administrative capital for the Central Tongu District. Primary health care is provided by the district hospital located in Adidome and also supported by a number of CHIPS compounds. Malaria transmission in these areas is perennial with two transmission peaks during rainy seasons in April-July and September–November. The entomological inoculation rate (EIR) for the Volta region was approximately 65 (95% CI: 0–143) infectious bites per person per year in 2008 [9] and the main vector is *Anopheles gambiae*.
**Study design and sample collection**
The study was designed as hospital-based cross-sectional surveys to recruit pregnant women visiting Battor and Adidome hospital for their first prenatal visit (ANC) and for delivery. Standardized questionnaires and checklists were used to collect demographic and clinical data both at first ANC and delivery. At first ANC, only HIV-negative pregnant women who had not received any prophylaxis against malaria were recruited into the study after their consent were obtained. Peripheral blood was collected into an EDTA tube, as well as blood spots on filter paper before administration of IPTp-SP. Haemoglobin (Hb) levels were measured at the hospital laboratory, and results recorded in participants’ ANC booklets and ANC records books. The participants ANC booklets are pregnancy information booklets given to each pregnant women in order to facilitate the pregnancy follow-up. The ANC records are hospital’s files with records about all pregnant women coming at the hospital.

At delivery, the number of IPTp-SP dose uptake, parity status and complementary clinical data such as the number of ANC visits, any type of complication experienced during pregnancy, type of delivery, Hb level and birth weight were obtained from participants’ ANC booklets. Peripheral and placental blood from each participant was also collected into separate EDTA vacutainer tubes, blood spots were made and the mother’s peripheral blood Hb level measured at the hospital’s laboratory.

For all participants, parasite detection was performed at the hospital either by RDT when available or microscopy. All blood samples were centrifuged and each blood component (plasma and red blood cell pellets) stored either at −20°C or −80°C for further analysis.

Women recruited during ANC were included in the analysis if they had essential information such as age, parity status, maternal haemoglobin levels, as well as malaria qPCR results on the peripheral blood at the time of inclusion. At delivery, pregnant women were included in the analysis if, in addition to the above-mentioned criteria, there were records of the number of antenatal IPTp-SP doses administered, as well as malaria qPCR results for both peripheral and placental blood at the time of delivery.

**DNA extraction and parasite detection by PCR**
DNA was extracted from the blood spots on filter paper using the Chelex method [20]. The presence of *P. falciparum* DNA in the extracted DNA was examined in duplicate by qPCR amplifying 18S rRNA, as previously described [21]. Samples without amplicons (no cycle thresholds detected) were considered negative. Purified parasite DNA from the 3D7 strain was used as a positive control, while a negative control with no DNA template was run in parallel.

**Genotyping of Pfdhfr and Pfdhps**
The *Pfdhfr* and *Pfdhps* genes of *P. falciparum* were amplified as previously described [22]. The PCR products were purified and sequenced using the Sanger method (GATC, Cologne, Germany). All generated sequences were analysed with the Chromas software [23], then aligned using the Muscle software [24] and compared to the 3D7 *P. falciparum* reference genome.

**Statistical analysis**
At delivery, the main variable of interest was IPTp-SP uptake, and it was grouped into 3 categories; women who did not receive any IPTp-SP dose, women who received 1 or 2 doses, and women who received ≥ 3 doses of IPTp-SP. Parasitological outcomes were compared between groups by univariate analysis and logistic or linear regression models. Changes in maternal haemoglobin levels and birthweight were assessed using linear regression models and stratified by IPTp-SP dosing. The adjustment factors were gravidity (primigravidae or multigravidae), infection status (positive or negative by PCR) anaemia status at time of sampling and SP uptake from the ANC booklet. Student’s t test and chi squared test were used to compare participant’s baseline characteristics and to determine the association between the *pfdhps* A581G mutation and the number of doses of SP taken where appropriate.

P-values of less than 0.05 were considered as statistically significant. Stata version 13 was used for data analysis and GraphPad version 5.01 for graphical depiction of data.

**Results**

**Study population characteristics**
A total of 932 pregnant women were recruited at the first ANC and 617 women at delivery. At the end, 692 women out of 932 (366 from Adidome and 326 from Battor) were included in the analysis for ANC versus 499 (284 in Adidome and 215 in Battor) for women recruited at delivery. The characteristics of the participants were similar between the two study sites, except for age (*p* = 0.003), gestational age (*p* < 0.0001), and Hb level (*p* = 0.004) at ANC (Table 1). Pregnant women recruited at first ANC at Adidome were generally younger and had a lower gestational age at the time of their first antenatal care visits (Age = 25.81 ± 6.39; Gestational age = 13.93 ± 7.05) compared to those recruited at Battor (Age = 27.44 ± 6.01; Gestational age = 16.53 ± 8.20). Pregnant women from Battor had higher haemoglobin levels (11.36 ± 1.15) compared to those from Adidome (10.61 ± 1.44).
Of the women who attended their first ANC, only 77.3% (297/384) at Adidome and 81.9% (267/326) at Battor had microscopy data, because the results of some blood smears were considered uncertain due to poor quality and therefore excluded. For the women retained, *Plasmodium falciparum* prevalence detected by microscopy at Adidome and Battor was 12.5% (37/297) and 6.4% (17/267), respectively. When assessed by qPCR, the prevalence increased to 28.4% (104/366) and 18.1% (59/326) in Adidome and Battor, respectively.

At delivery, *P. falciparum* prevalence by microscopy was 0.7% (2/284) and 0% (0/215), respectively, and was 14.1% (40/284) and 7.9% (17/215) at Adidome and Battor when detected by qPCR. *P. falciparum* prevalence in placental samples determined by qPCR at delivery was 16.5% (47/284) at Adidome against 3.3% (7/215) at Battor (Table 2).

### Table 1
General characteristics of the study population

| Characteristics                              | 1st ANC Overall (n = 692) | Adidome (n = 366) | Battor (n = 326) | p-value | Delivery Overall (n = 499) | Adidome (n = 284) | Battor (n = 215) | p-value |
|---------------------------------------------|----------------------------|-------------------|------------------|---------|----------------------------|-------------------|------------------|---------|
| Age (Mean ± SD)                             | 26.59 ± 5.14               | 25.81 ± 6.39      | 27.44 ± 6.01     | **      | 26.98 ± 4.76               | 26.88 ± 6.07      | 27.26 ± 5.31     |         |
| Gravidity/Parity (n (%))                    |                            |                   |                  |         |                            |                   |                  |         |
| Primigravidae                               | 204 (29.48%)               | 114 (31.06%)      | 90 (27.69%)      |         | 117 (23.44%)               | 65 (23.13%)       | 52 (26.40%)      |         |
| Multigravidae                               | 488 (70.52%)               | 253 (68.94%)      | 235 (72.31%)     |         | 361 (72.34%)               | 216 (76.87%)      | 145 (73.60%)     |         |
| Gestational age in weeks (Mean ± SD)        | 15.16 ± 5.86               | 13.93 ± 7.05      | 16.53 ± 8.20     | ***     | 38.84 ± 1.41               | 38.75 ± 1.78      | 38.98 ± 1.74     |         |
| Bed net possession (n (%))                  |                            |                   |                  |         |                            |                   |                  |         |
| Yes                                         | 644 (93.06%)               | 338 (92.10%)      | 306 (94.74%)     |         | 454 (90.98%)               | 257 (94.83%)      | 197 (95.63%)     |         |
| No                                          | 46 (6.65%)                 | 29 (7.90%)        | 17 (5.26%)       |         | 23 (4.61%)                 | 14 (5.17%)        | 9 (4.37%)        |         |
| Bed net usage (n(%))                        |                            |                   |                  |         |                            |                   |                  |         |
| Always                                      | 466 (67.34%)               | 238 (64.85%)      | 228 (70.59%)     |         | 267 (53.51%)               | 162 (60.90%)      | 105 (50.97%)     |         |
| Sometimes                                   | 177 (25.58%)               | 104 (28.34%)      | 73 (22.6%)       |         | 169 (33.87%)               | 89 (33.46%)       | 80 (38.83%)      |         |
| Seldom                                      | 47 (6.79)                  | 25 (6.81%)        | 22 (6.81%)       |         | 17 (3.41%)                 | 5 (1.88%)         | 12 (5.83%)       |         |
| HBX (Mean ± SD)                             | 10.73 ± 1.13               | 10.61 ± 1.44      | 11.36 ± 1.15     | **      | 10.77 ± 0.93               | 10.79 ± 1.22      | 10.71 ± 1.87     |         |
| Anaemia status (n (%))                      |                            |                   |                  |         |                            |                   |                  |         |
| Severe anaemic (Hb < 8.0 g/dL)              | 14 (2.23%)                 | 14 (4.6%)         | 0 (0%)           |         | 16 (3.21%)                 | 8 (2.85%)         | 8 (5.88%)        |         |
| Anaemic (11.0 < Hb ≥ 8.0 g/dL)              | 168 (24.28%)               | 154 (50.66%)      | 14 (25%)         |         | 209 (41.88%)               | 135 (48.04%)      | 74 (54.41%)      |         |
| Birth Outcome (Mean ± SD)                   |                            |                   |                  |         |                            |                   |                  |         |
| Low birth weight < 2500 g                   | 38 (5.62%)                 | 21 (7.45%)        | 17 (9.82%)       |         |                            |                   |                  |         |

*p ≤ 0.05; **p < 0.01; ***p < 0.001

### Table 2
Plasmodium falciparum prevalence at both study sites and at 1st ANC and Delivery

| Characteristics                              | 1st ANC Overall (n = 692) | Adidome (n = 366) | Battor (n = 326) | p-value | Delivery Overall (n = 499) | Adidome (n = 284) | Battor (n = 215) | p-value |
|---------------------------------------------|----------------------------|-------------------|------------------|---------|----------------------------|-------------------|------------------|---------|
| Peripheral infection*                       |                            |                   |                  |         |                            |                   |                  |         |
| By microscopy                               | 52 (0.22%)                 | 37 (12.42%)       | 15 (5.64%)       |         | 2 (0.4%)                   | 2 (3.77%)         | 0                |         |
| By qPCR                                     | 163 (23.55%)               | 104 (28.4%)       | 59 (18.1%)       |         | 57 (11.42%)                | 40 (14.1%)        | 17 (7.9%)        |         |
| Parasite density*                           |                            |                   |                  |         |                            |                   |                  |         |
| By qPCR                                     | 3086 ± 5886                | 5308 ± 85,068     | 693 ± 6332       |         | 7320 ± 14,328              | 11,566 ± 66,809   | 4669 ± 34,805    |         |
| Placental infection                         |                            |                   |                  |         |                            |                   |                  |         |
| By qPCR                                     | 54 (10.82%)                | 47 (16.5%)        | 7 (3.3%)         |         |                            |                   |                  |         |

*n (%) ; #Mean ± SD
IPTp-SP coverage

Since IPTp-SP was given under direct observation therapy (DOT), information on uptake by pregnant women at delivery was obtained from their antenatal booklets as a source of IPTp-SP uptake. Among the 499 pregnant women recruited at delivery, 94.8% (473/499) had data on IPTp-SP uptake. Among these, 97% (459/473) took at least one dose of IPTp, 66.2% (313/473) took 3 or more IPTp-SP doses, while 31% (146/473) took one or two doses. Fourteen pregnant women reported no IPTp-SP uptake due to non-attendance at ANC.

When the data were stratified by study site, at Adidome 283 of the 284 women recruited had data on IPTp-SP uptake. One hundred and eighty-five women (65.4%) received 3 or more IPTp-SP doses, 18.7% (53/283) received two IPTp-SP doses and 12.4% (35/283) received one IPTp-SP dose. Ten women reported no IPTp-SP uptake due to non-attendance at ANC visit. At Battor, 88.4% (190/215) of pregnant women recruited at delivery had information on IPTp-SP uptake. Out of this number, 67.4% (128/190) received 3 or more IPTp-SP doses, 16.8% (32/190) received two IPTp-SP doses and 13.7% (26/190) received only one IPTp-SP dose. Four women reported no IPTp-SP due to non-attendance at ANC (Fig. 1).

Impact of IPTp-SP uptake on birth weight

Overall multivariate regression analysis showed that uptake of 3 or more IPTp-SP doses increased the average birthweight by 360 g compared to babies born to mothers who did not take treatment (p = 0.03). Although an increase in birthweight of 250 g was also observed among infants born to women who took only 1 or 2 IPTp-SP doses, this was not statistically significant (p = 0.14). As expected, children born to primigravid mothers weighed on average 250 g less than those born to multigravidae (p < 0.0001) (Table 3).

Prevalence of Pf dhfr and Pf dhps mutations

A total of 120 P. falciparum isolates were sequenced, of which, 73.3% (88/120) were from pregnant women recruited at ANC (58% from Adidome and 42. % from Battor) and 26.7% (32/120) from pregnant women recruited at Delivery (31.3% from Battor and 68.7% from Adidome). Of the 120 isolates sequenced, 93.3% (112/120) were successfully amplified, sequenced and genotyped for Pf dhfr and 87.5% (105/120) for Pf dhps.

A high prevalence of nonsynonymous mutations of three codons of Pf dhfr and two codons of Pf dhps was detected among the parasite isolates. Regarding Pf dhfr, the prevalence of a mutant allele at codon 108 (S108N, 98.2%, 110/112) was predominant; followed by that of codon 59 (C59R, 97.3%, 109/112) and 51 (N51I, 89.3%, 104/112). However, only one mutation was observed at codon 164 (1164L, 0.9%, 1/112). Similarly, a high

Table 3 Relationship between birth weight and SP uptake by multivariate regression

| Coefficients (g) 95% CI | p-value |
|------------------------|---------|
| No SP uptake Reference |
| Overall effect |
| 1 or 2 IPTp-SP uptake\(^a\) 250 [−0.08; 0.57] 0.137 |
| ≥ 3 IPTp-SP uptake\(^b\) 360 [0.04; 0.68] 0.028 |
| Multigravidae Reference |
| Primigravidae |
| − 250 [−0.36; −0.13] < 1e−04 |

\(^a\) SP uptake of less than 3 doses (1 or 2 SP uptake) reflecting the old IPTp-SP policy recommendation
\(^b\) SP uptake of 3 or more doses reflecting the proxy of the 2012 recommendation

Fig.1 IPTp-SP coverage among pregnant women at Adidome and Battor. 0dose = Women who did not take SP during pregnancy Dose < 2 pregnant women who took 1 or 2 doses as recommended by the old regimen. Dose > 2 pregnant women who took at least 3 doses as recommended by the new regimen.
prevalence of a mutation at codon 437 (A437G, 97.1% (102/105) of the Pfdhps gene was observed followed by that of 436 (S436A/F, 72.4%, 76/105). Additionally, mutations were observed respectively at codons 581 (A581G, 21%, 22/105) and 613 (A613S/T, 4.8%, 5/105). However, no mutation was detected at codon 540 (Table 4). The analysis was then focused on the nonsynonymous mutation A581G and showed that mutant alleles (A581G) were preferentially found at delivery following IPTp-SP treatment (40.6%), compared to inclusion (10.22%) (Ratio of first ANC/delivery 1:3.9; *p* = 0.001) (Table 5).

When the Pfdhfr/Pfdhps haplotypes were combined for the 105 parasites for whom sequence data was obtained; 16 haplotypes were observed (Table 6). Isolates with quintuple mutations including triple Pfdhfr IRN1 and double Pfdhps A/F/GKAA was the most common combined trait seen at a rate of 46.7% (49/105), followed by the quadruple combined trait (IRN1-S/GKAA) at 16.2% (17/105). The occurrence of other combined genotypes was generally low and comprised between 1 and 8%.

**Discussion**

The SP drug, currently used as intermittent preventive treatment during pregnancy (IPTp-SP), remains a fundamental component in the strategy to protect pregnant women from malaria and its adverse effects on pregnancy outcome. Yet, its adaptation and utilization had been unexpectedly sub-optimal, while several studies showed its inability to provide protection from malaria, especially in the third trimester [25]. Combined, this prompted a policy review to increase its utilization and coverage in the third trimester [25]. The initial implementation of the new IPTp-SP policy. Indeed, it needs to be repeated on a regular basis to monitor the preservation of this added value, as it could over time, lead to other suspected consequences on parasite resistance that could mitigate clinical benefit. The policy of increasing treatment doses certainly applies an increased drug-selection pressure on parasites and therefore, it must be regularly assessed to inform decision-makers.

Here, two different sets of pregnant women living in rural areas on the banks of the Volta river in Ghana were enrolled: those visiting health centres for their first ANC and the second set coming to deliver the babies at health centres. The design of the present study makes it possible to capture the characteristics of women appearing at their first ANC and to determine their usage of IPTp-SP, as part of the strategy for malaria prevention during pregnancy in the delivery cohort. The first observation is early attendance of ANC, women arriving on average between 14 and 16th week of pregnancy. This early attendance to an ANC is a determining factor for the successful implementation of the new IPTp-SP policy. Indeed, it

| Gene | category | Haplotype | n (%) |
|------|----------|-----------|-------|
| Pfdhfr/pfdhps (n = 105) | wild type | NCSI-SAKAA | 0 |
|     | double   | I_SG/KAA  | 1 (0.95%) |
|     | triple   | IRN/S/GKAA 2 (1.9%) |
|     | quadruple | IRN/S/GKAA 17 (16.19%) |
|     | quintuple | IRN/S/F/KAA 3 (2.90%) |
|     | sixtuple  | IRN/S/F/GKAA 8 (7.6%) |
|     | septuple  | IRN/S/F/G/S/T 49 (46.7%) |
|     | IRN/S/GK 9 (8.57%) |
|     | IRN/S/F/G 1 (0.95%) |
|     | IRN/S/F/K 1 (0.95%) |
|     | IRN/S/F/G/S 1 (0.95%) |
|     | IRN/S/F/G/S/T 2 (1.90%) |
|     | IRN/S/F/G/S 6 (5.71%) |
|     | IRN/S/F/G/S/T 1 (0.95%) |
|     | IRN/S/F/G/S 2 (1.90%) |

| Table 5 | A581G mutation at first ANC visit and at delivery |
|---------|--------------------------------------------------|
| No. of positive isolates (%) | p-value |
| Mutated codons at Dhps |
| S81 | First ANC (n = 88) | Delivery (n = 32) | 0.001 |
| + | 9 (10.22%) | 13 (40.6%) |

+: presence of A581G mutation

need to be repeated on a regular basis to monitor the preservation of this added value, as it could over time, lead to other suspected consequences on parasite resistance that could mitigate clinical benefit. The policy of increasing treatment doses certainly applies an increased drug-selection pressure on parasites and therefore, it must be regularly assessed to inform decision-makers.

Here, two different sets of pregnant women living in rural areas on the banks of the Volta river in Ghana were enrolled: those visiting health centres for their first ANC and the second set coming to deliver the babies at health centres. The design of the present study makes it possible to capture the characteristics of women appearing at their first ANC and to determine their usage of IPTp-SP, as part of the strategy for malaria prevention during pregnancy in the delivery cohort. The first observation is early attendance of ANC, women arriving on average between 14 and 16th week of pregnancy. This early attendance to an ANC is a determining factor for the successful implementation of the new IPTp-SP policy. Indeed, it

| Table 6 | Prevalence of combined pfdhfr/pfdhps haplotypes in study isolates |
|---------|--------------------------------------------------|
| Gene | category | Haplotype | n (%) |
|-------|----------|-----------|-------|
| Pfdhfr | wild type | NCSI-SAKAA | 0 |
|       | double   | I_SG/KAA  | 1 (0.95%) |
|       | triple   | IRN/S/GKAA 2 (1.9%) |
|       | quadruple | IRN/S/GKAA 17 (16.19%) |
|       | quintuple | IRN/S/F/KAA 3 (2.90%) |
|       | sixtuple  | IRN/S/F/GKAA 8 (7.6%) |
|       | septuple  | IRN/S/F/G/S/T 49 (46.7%) |
|       | IRN/S/GK 9 (8.57%) |
|       | IRN/S/F/G 1 (0.95%) |
|       | IRN/S/F/K 1 (0.95%) |
|       | IRN/S/F/G/S 1 (0.95%) |
|       | IRN/S/F/G/S/T 2 (1.90%) |
|       | IRN/S/F/G/S 6 (5.71%) |
|       | IRN/S/F/G/S/T 1 (0.95%) |
|       | IRN/S/F/G/S 2 (1.90%) |
is essential that women arrive early at an ANC to offer more time to receive a maximum of treatment doses over a longer period of pregnancy [26]. This observation in rural areas is particularly important, because it’s similar to that made in urban areas in a previous study by Quakyi et al. [5] and clearly indicates that sensitization of women in Ghana for their early participation in ANCs has been relayed across the country. This is in particular due to the National Malaria Control Programme’s (NMCP) efforts in promoting awareness combined with improved education of the risk to pregnant women at ANC. Data from this study shows that 66% of participants received three or more IPTp-SP doses. This finding is also consistent with previous investigations in other parts of Ghana reporting that more than 60% of pregnant women took at least three IPTp-SP doses [5, 27]. It is interesting to note that the fairly satisfactory coverage of IPTp-SP in Ghana does not seem to differ significantly among community settings across the country. The study shows that a small number of women (N = 14) nevertheless reported not taking IPTp-SP during pregnancy due to not attending ANC. This confirms the importance of ANC attendance in IPTp-SP coverage, especially since it is administered in Ghana only as a direct observation therapy (DOT). It appears, therefore, legitimate to further consider the involvement of communities in the delivery of IPTp-SP to all eligible pregnant women, as this would help reduce the number of women not taking IPTp-SP due to their non-attendance at an ANC.

In this study, a beneficial effect of IPTp-SP on birth weight was observed. In this instance, uptake of ≥ 3 SP doses was clearly associated with an increase in birth weight at the two study sites by 360 g (Table 3). The association of more IPTp-SP doses with increased birthweight was obvious in both primigravid and multigravid women and consistent with a study by Desai et al. [11] and Quakyi et al. [5] that reported reduced risk of LBW among pregnant women living in medium–high SP resistant areas. In this study, no association between IPTp-SP dosage and parasite density or placental infection at delivery was observed, as in other studies [6, 28]. As discussed previously by Quakyi et al. [5], the lack of an observable link in this non-longitudinal study is not surprising and does not necessarily reflect any lack of effect on parasites. It’s still plausible that the effect of SP treatment on other non-malarial infections (especially sexually transmitted infections) indirectly contributes to this observed beneficial effect on birth weight. Also, an association was not found between uptake of ≥ 3 SP doses and anaemia confirming the finding of Agyeman et al. [29]; IPTp-SP alone doesn’t protect pregnant women from anaemia, because anaemia in pregnancy is multifactorial and involves other factors such as nutrition.

Further, the study shows a high prevalence of Pfδhfr/Pfδhps quintuple mutations in parasite isolates from both study sites, but unlike what is happening in East Africa, no Pfδhps K540E mutation was found [30]. This result indicates that Pfδhps K540E mutation conferring a high level of resistance to SP has not yet emerged at the study areas, although it has been detected at very low frequency at different communities in southern Ghana [15].

Between first ANC and delivery, the prevalence of the A581G Pfδhps mutation increased approximately 3.9-fold in the study population, suggesting that IPTp-SP use may possibly select the Pfδhps A581G mutation. This observation is further supported by the fact that the prevalence of Pfδhps A581G mutation increased with the number of SP doses taken, as also described by Tornyiah et al. [15]. The correlation of this mutation with IPTp-SP treatment is consistent with selection due to drug pressure. It has been shown that Pfδhps A581G mutation occurring on a Pfδhfr/Pfδhps quintuple mutation background was associated with higher risks of infection in Malawian pregnant women [31]. Also, no correlation was found between parasite density and the frequency of the Pfδhps A581G mutation at the study sites. However, the increase in the prevalence of Pfδhps A581G mutation at delivery and the emergence of the sextuple mutation (IRNI-A/FGKGS/T) raises the question of whether a possible increase in the prevalence of parasites carrying the sextuple mutation could gradually lead to IPTp-SP drug failure in Ghana.

The results obtained during this study showed that parasite SP resistance background did not affect birth weight outcomes as IPTp-SP was associated with an increase in birth weight in the study sites but also as shown in different communities in southern Ghana irrespective of SP resistance [5]. This finding may be due to secondary non-malaria related effects (bacterial or fungal genital infections for instance), that also impact on fetal growth and maternal health [32]. Therefore, it would be interesting to examine the effect of SP on birth weight independent of malaria infection.

Despite the high prevalence of Pfδhfr/Pfδhps quintuple mutations and even the existence of sextuple mutations, IPTp-SP continues to prove its beneficial effect on birth weight at delivery in Ghanaian pregnant women.

Study limitations

Although this study made it possible to highlight some important associations, it nevertheless has some limitations which need to be pointed out. One of them has been the inability of the team to have sufficient microscopy data at the time of delivery to be able to study the
part of associations attributable to microscopic and sub-microscopic infections. Although there was an attempted to control known confounders in the design and at the analysis stage, it is possible that the use of ITNs among participants that have not been included in the analysis could have influenced the various observations made. The fact that this study was observational and did not involve any intervention allowed to have a real picture of what is happening on the field, but remains a weakness because they only offer one point of observation.

Conclusions

The NMCP target is to treat all pregnant women with IPTp-SP even though this will undoubtedly lead to a drastic increase of SP-induced drug pressure on parasite populations. Thus, an increase in A581G mutation prevalence and/or emergence of the K540E mutation must be carefully documented to assure long-term IPTp-SP efficacy and performed in parallel with implementation of field studies on alternatives to IPTp-SP such as other anti-malarial drug combinations or a malaria vaccine for pregnant women.

Abbreviations

ANC. Antenatal care visit or Antenatal care consultation; CHPS. Community-based Health Planning and Services; DOT. Direct observation therapy; EIR: Entomological inoculation rate; Hb: Haemoglobin; IPTp. Intermittent preventive treatment of malaria in pregnancy; LBW: Low birth weight; MiP: Malaria in pregnancy; NMCP: National Malaria Control Programme; NMIMR: Noguchi Memorial Institute for Medical Research; RDT: Rapid diagnostic test; SP: Sulfadoxine-pyrimethamine; WHO: World Health Organization.

Acknowledgements

We are grateful to all the women who participated in the study. We thank the staff of the study sites (Battor Catholic Hospital and Adidome district Hospital) for their contribution to participant enrollment and samples collection. Special thanks to Dr. Gordon Langsley for helping to edit this manuscript, to Renosten Tetteh and Tatiana Hountohotegbe for their help in the laboratory.

Authors’ contributions

NTN, DC, AKA, MFO and KAX contributed to the design of the MAHEVA study; AM, CA, NAF and BT collected the samples and carried out all the lab experiments; AM, BT, NTN and AF performed the sequence analysis and statistical analysis; AM, AF, and NTN wrote the paper; BT, BA, SH, PD, KAX, FA and NTN reviewed the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by the French Institute for Sustainable Development (IRD) under the call for the creation of the young team associated with the IRD (JEAI-MAHEVA), and of the international joint laboratory (LMI-CONSHELM). A.M. was supported by Labex Parafrap South Ph.D. fellowship. The project was funded by IRD.

Availability of data and materials

The datasets analysed for this study are included in the article, additional data required are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Ethical clearance was obtained from the Institutional Review Board of the Noguchi Memorial Institute for Medical Research (NMIMR) and from the Ethical Review Committee of the Ghana Health Service. Written informed consent was obtained from each participant or their guardians for those under 18 years prior to recruitment into the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Université de Paris, MÉRIT, IRD, 75006 Paris, France. 2. Department of Parasitology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana. 3. INSERM 1016, Service de Parasitologie-Mycologie Hôpital Cochin, Université de Paris, 75014 Paris, France. 4. Department of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana. 5. Department of Science Laboratory Technology, Faculty of Applied Sciences, Accra Technical University, P O Box GP 561, Accra, Ghana. 6. Centre National de Référence du Paludisme, Hôpital Bichat-Claude Bernard, APHP, 75018 Paris, France.

Received: 1 July 2021 Accepted: 13 March 2022

Published online: 26 March 2022

References

1. Doritchamou JYA, Morrison R, Renn JP, Ribeiro J, Duan J, Fried M, et al. Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some Plasmodium falciparum strains. Commun Biol. 2019;2:457.
2. Malaria Policy Advisory Committee to the WHO. Conclusions and recommendations of eighth biannual meeting (September 2015). Malar J. 2016;15:117.
3. Oppong FB, Gyase S, Zandoh C, Nettey OEA, Amenga-Etego S, Anane EA, et al. Intermittent preventive treatment of pregnant women in Kintampo area of Ghana with sulphadoxine-pyrimethamine (SP): trends spanning 2011 and 2015. BMJ Open. 2019;9:e027946.
4. Eisele TP, Larsen DA, Anglewicz PA, Keating J, Yukiw R, Bennett A, et al. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect Dis. 2012;12:942–9.
5. Quaiyi J, Tomyiyag B, Houze P, Kusi KA, Coleman N, Escrivou G, et al. High uptake of Intermittent Preventive Treatment of malaria in pregnancy is associated with improved birth weight among pregnant women in Ghana. Sci Rep. 2019;9:19034.
6. Kayentao K, Garner P, Ejik A, Naidoo I, Roper C, Mulokozzi A, et al. Intermittent Preventive Therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA. 2013;309:594–604.
7. Ovwusu-Boateng L, Anto F. Intermittent preventive treatment of malaria in pregnancy: a cross-sectional survey to assess uptake of the new sulfadoxine–pyrimethamine five dose policy in Ghana. Malar J. 2017;16:323.
8. Anto F, Agongo IH, Asioala V, Awiin E, Odoro AR. Intermittent preventive treatment of malaria in pregnancy: assessment of the sulfadoxine–pyrimethamine three-dose policy on birth outcomes in rural Northern Ghana. J Trop Med. 2019;2019:6712685.
9. Kweku M, Appiah EK, Takramah W, Enumah Y, Norman I, Birks F. Effect of a malaria control program on the prevalence of malaria, fever and anaemia in children under five years in the Hohoe municipality of Ghana: a comparative analysis of cross-sectional surveys. Adv Infect Dis. 2015;5:180–8.
10. Walker PGT, Floyd J, Kuile F, Cairns M. Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy
given sulphadoxine-pyrimethamine resistance in Africa: a mathematical model. PLoS Med. 2017;14(1):e1002243.

11. Desai M, Gutman J, Taylor SM, Wiegand RE, Khairallah C, Kayentao K, et al. Impact of sulphadoxine-pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low birth weight. Clin Infect Dis. 2016;62:323–33.

12. Kayentao K, Kodio M, Newman RD, Maiga H, Dountabé D, Onogbo A, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis. 2005;191:109–16.

13. White NJ. Intermittent presumptive treatment for malaria. PLoS Med. 2005;2:e3.

14. Maiga OM, Kayentao K, Traore BT, Djimde A, Traore B, Diallo M, et al. Superiority of 3 over 2 doses of intermittent preventive treatment with sulphadoxine-pyrimethamine for the prevention of malaria during pregnancy in Mali: a randomized controlled trial. Clin Infect Dis. 2011;53:215–23.

15. Tornyigah B, Coppée R, Houze P, Kusi KA, Adu B, Quayk I, et al. Effect of drug pressure on promoting the emergence of antimalarial-resistant parasites among pregnant women in Ghana. Antimicrobial Agents Chemotherapy. 2020;64:e02029-e2119.

16. Massougbdjio A, Tubert-Bitter P, Briand Y, Journot V, Cot M, Escolano S. Mefloquine versus sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy: a joint analysis on efficacy and tolerability. Am J Trop Med Hyg. 2015;93:300–4.

17. Roh ME, ter Kuile FO, Rerolle F, Glymour MM, Shiboski S, Gosling R, et al. Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine on birth-weight: a mediation analysis. Lancet Global Health. 2020;8:e942–53.

18. Stoner MCD, Vwalika B, Smid M, Kumwenda A, Stringer E, Chi BH, et al. Dosage of sulphadoxine–pyrimethamine and risk of low birth weight in a cohort of Zambian pregnant women in a low malaria prevalence region. Am J Trop Med Hyg. 2017;96:170–7.

19. Malaria Indicator Survey 2016. https://www2.statsghana.gov.gh/dpdf/publications/IMIS26.pdf

20. Plowe CV, Djimde A, Bouare M, Doundo O, Wellemes TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565–8.

21. Taylor SM, Mayor A, Mombo-Ngoma G, Kenguele HM, Ouedraogo S, Ndam NT, et al. A quality control program within a Clinical Trial Consortium for PCR protocols to detect Plasmodium species. J Clin Microbiol. 2014;52:2144–9.

22. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of Northern Tanzania. Antimicrob Agents Chemother. 2003;47:1347–54.

23. Goodstadt L, Ponting CP. CHROMA: consensus-based colouring of multiple alignments for publication. Bioinformatics. 2001;17:845–6.

24. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792–7.

25. Moussiouli A, De Tove YS-S, Dortrichamou J, Luty AJ, Massougbdjio A, Afifrangis M, et al. High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J. 2013;12:195.

26. Odjidja EN, Kwanin C, Saha M. Low uptake of intermittent preventive treatment in Ghana; an examination of health system bottlenecks. Health Syst Policy Res. 2017;4:60.

27. Darthe EMK, Buabeng I, Akaromah-Boateng C. Uptake of intermittent preventive treatment in pregnancy for malaria: further analysis of the 2016 Ghana Malaria Indicator Survey. J Public Health (Berl). 2021;29:967–78.

28. Mpongore FJ, Matovelo D, Dosani A, Ngalaba S, Mugono M, Mazigo HD. Uptake of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in Geita district. North-Western Tanzania Malar J. 2014;13:455.

29. Agyeaman YN, Newton S, Annon RB, Owusu-Dabo E. Intermittent preventive treatment comparing two versus three doses of sulphadoxine-pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study. PLoS ONE. 2021;16:e0250350.

30. Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, et al. The A581G mutation in the gene encoding Plasmodium falciparum dihydropteroate synthetase reduces the effectiveness of sulphadoxine-pyrimethamine preventive therapy in Malawian pregnant women. J Infect Dis. 2015;211:1997–2005.

31. Lin JT, Mbwewa B, Taylor SM, Luntamo M, Meshnick SR, Ashorn P. Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria. Trop Med Int Health. 2013;18:175–8.

32. Chico RM, Chaponda EB, Anti C, Chandramohan D. Sulfadoxine-pyrimethamine exhibits dose-response protection against adverse birth outcomes related to malaria and sexually transmitted and reproductive tract infections. Clin Infect Dis. 2017;64:1043–51.